GlassScriptPhysician profile
James M Shipley
NPI 1912957937
$1,655.02
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $257 · 2021: $527 · 2022: $410 · 2023: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $376.18 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $205.20 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $138.29 | 2019-2022 | |
| Pfizer INC. | $117.29 | 2019-2023 | |
| Lilly USA, LLC | $101.07 | 2020-2023 | Emgality, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $66.70 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.85 | 2022-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $56.60 | 2022 | |
| Glaxosmithkline, LLC. | $54.29 | 2019-2022 | |
| Amgen INC. | $51.87 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $47.86 | 2020 | |
| Idorsia Pharmaceuticals US INC | $44.85 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $44.35 | 2022-2023 | Gvoke Hypopen |
| Neurelis, INC. | $40.51 | 2021 | |
| Eisai INC. | $32.03 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.13 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2023 | Rexulti |
| Grt US Holding, INC. | $17.80 | 2022 | |
| Inogen, INC. | $16.10 | 2022 | |
| Exact Sciences Corporation | $15.84 | 2023 | Cologuard Collection Kit |
| Corium, LLC | $15.78 | 2023 | Adlarity |
| Merck Sharp & Dohme LLC | $15.21 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2023 | Tradjenta, Jardiance |
| Biodelivery Sciences International, INC. | $14.86 | 2021 | |
| Sanofi Pasteur INC. | $13.44 | 2019 | |
| Evoke Pharma, INC. | $13.34 | 2022 | |
| Advanced Respiratory, INC | $12.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.26 | 2022 | |
| Dexcom, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Shipley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.